NCT02674854View on ClinicalTrials.gov

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

PG324 Ophthalmic Solution 0.02%/0.005%

1 drop daily in the evening (PM) in both eyes (OU)

DRUG

Netarsudil (AR-13324) ophthalmic solution 0.02%

1 drop daily in the evening (PM) in both eyes (OU)

DRUG

Latanoprost ophthalmic solution 0.005%

1 drop daily in the evening (PM) in both eyes (OU)

Trial Locations (1)

07921

Aerie Pharmaceuticals, Bedminster

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT02674854 - Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter